OR WAIT null SECS
July 01, 2014
Bristol-Myers Squibb issues a voluntary US recall of Coumadin (warfarin sodium) for injection due to presence of particulate matter.
June 26, 2014
GSK Biologicals receives warning about cGMP compliance issues at its Quebec facility.
June 18, 2014
FDA cites cGMP violations for API manufacturing at a facility in Tianjin, China.
FDA inspection found cGMP violations in the Bangalore, India API manufacturing facility.
June 17, 2014
ISPE Metrics Pilot Program is designed to demonstrate the feasibility and value of standard quality metrics.
June 06, 2014
Despite GMP deficiencies, EMA reinstates GMP certificate for Ranbaxy's Toansa facility, citing no threat to public health.
May 19, 2014
Hospira has recalled one lot of labetalol hydrochloride injection, USP, due to visible particulates.
February 25, 2014
Daiichi Sankyo announced suspension of API shipments from Ranbaxy's Toansa and Dewas plants; issues apology to stakeholders.
January 24, 2014
FDA adds Ranbaxy's Toansa, India facility to existing consent decree, prohibiting distribution of APIs from that location
January 22, 2014
Online portal accepts nominations for FDA advisory committee membership.